Benzinga

Benzinga

Benzinga

sábado, agosto 29

Pacific Biosciences of California Inc

PACBNASDAQ
Trade with Public
Trade with Public
$1.40
-0.15-9.68%
al cierre: Aug 28, 5:00 PM EST
$1.42
0.021.43%
After hour: 7:48 PM EST
Panorámica generalNoticiasPrevisión de beneficiosEventosPrecios objetivoFinanzasSentimientoPropiedadCompararOpcionesInforme de acciones

Pacific Biosciences Analyst Price Targets

Wall Street analyst price targets and consensus rating for Pacific Biosciences (PACB).

Price Target Range — 12 Quarters

Analyst Consensus — 12 Analysts

6Buy
5Hold
1Sell
Consensus RatingBuy# Analysts12Avg. Consensus PT$2Upside to Avg. PT+67.6%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
May 11, 2026BarclaysLuke SergottPT RaiseUnderweight$1→$2
Apr 14, 2026BarclaysLuke SergottPT CutUnderweight$2→$1
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Barclays Maintains Underweight on Pacific Biosciences, Raises Price Target to $1.5

Barclays analyst Luke Sergott maintains Pacific Biosciences (NASDAQ:PACB) with a Underweight and raises the price target from $1 to $1.5.
Benzinga Newsdesk

PRO
Barclays Downgrades Pacific Biosciences to Underweight, Lowers Price Target to $1.5

Barclays analyst Luke Sergott downgrades Pacific Biosciences (NASDAQ:PACB) from Equal-Weight to Underweight and lowers the price target from $2 to $1.5.
Benzinga Newsdesk

PRO
Barclays Maintains Equal-Weight on Pacific Biosciences, Raises Price Target to $2

Barclays analyst Luke Sergott maintains Pacific Biosciences (NASDAQ:PACB) with a Equal-Weight and raises the price target from $1.5 to $2.
Benzinga Newsdesk

PRO
Piper Sandler Maintains Neutral on Pacific Biosciences, Raises Price Target to $2

Piper Sandler analyst David Westenberg maintains Pacific Biosciences (NASDAQ:PACB) with a Neutral and raises the price target from $1.5 to $2.
Benzinga Newsdesk

PRO
Stephens & Co. Maintains Overweight on Pacific Biosciences, Raises Price Target to $2

Stephens & Co. analyst Mason Carrico maintains Pacific Biosciences (NASDAQ:PACB) with a Overweight and raises the price target from $1.8 to $2.
Benzinga Newsdesk

The Analyst Verdict: Pacific Biosciences In The Eyes Of 4 Experts

Benzinga Insights

Datos y APIs: APIs de Benzinga · API de noticias de acciones · API de calificaciones de analistas · API de logotipos de empresas

Datos de mercado proporcionados por APIs de Benzinga

Benzinga

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

© 2026 Benzinga | All Rights Reserved